Add BrightSurf on Google Email

Researchers may have solved decades-old mystery behind benzodiazepine side effects

A research team has identified a key protein suspected to be involved in benzodiazepine-related inflammation, which could inform strategies to improve benzodiazepine drug design and treat inflammation-related conditions. The findings may lead to new treatments for diseases such as Alzheimer's, arthritis, and multiple sclerosis.

SourceVirginia Commonwealth University·JournalProceedings of the National Academy of Sciences·DateApr 14, 2025

Cutting-edge optical genome mapping technology shows promise for diagnosis, prognosis, and therapeutic options of multiple myeloma

Researchers have developed an innovative optical genome mapping technique that can identify structural variants and copy number variations across the entire genome in a single test. The method has been shown to reduce material requirements and improve prognostic stratification for patients with multiple myeloma.

SourceElsevier·JournalJournal of Molecular Diagnostics·TypeExperimental study·DateApr 14, 2025

Marshall researchers explore gut microbiota’s role in sleep apnea in new review published in Sleep Medicine

A new review from Marshall University researchers highlights emerging connections between gut health and sleep apnea, pointing to potential new therapeutic approaches for managing this common disorder. Alterations in gut microbiota composition have been consistently observed in individuals with sleep apnea, inducing systemic inflammati...

SourceMarshall University Joan C. Edwards School of Medicine·JournalSleep Medicine·TypeLiterature review·DateApr 14, 2025

Mesenchymal stem cell-derived extracellular vesicles improve survival in mice exposed to high-dose irradiation

A new study found that mesenchymal stem cell-derived extracellular vesicles significantly enhance survival and facilitate substantial peripheral blood recovery in mice exposed to high-dose irradiation. The treatment promoted hematopoietic recovery, with increases in red blood cell, platelet, white blood cell, and hemoglobin levels.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalStem Cells and Development·TypeExperimental study·DateApr 9, 2025

Discovery of mitochondrial protein by researchers at Lewis Katz School of Medicine at Temple University opens path to therapeutic advances for heart and Alzheimer’s disease

Scientists have discovered a novel regulator of the mitochondrial sodium-calcium exchanger (NCLX), which helps maintain calcium balance in mitochondria. The discovery of TMEM65 could lead to new therapeutic agents to combat calcium overload associated with heart failure and Alzheimer's disease.

SourceTemple University Health System·JournalNature Metabolism·DateApr 8, 2025

Study: Platform-predicted treatments improve outcomes for platinum-resistant ovarian cancer

A Phase 3 trial found that ChemoID improves objective response rates, median progression-free survival, and duration of response in patients with recurrent platinum-resistant ovarian cancer. The test identifies effective treatments by challenging cancer stem cells against specific anticancer drugs.

SourceUniversity of Cincinnati·Journalnpj Precision Oncology·TypeRandomized controlled/clinical trial·DateApr 4, 2025

Groundbreaking consensus statement on conduction system pacing released: a major milestone in the evolution of pacing therapy

The European Society of Cardiology has released a groundbreaking consensus statement on conduction system pacing, offering updated guidance for healthcare professionals on selecting patients. Conduction system pacing is being increasingly adopted due to its perceived ease of implantation and superior electrical performance.

SourceEuropean Society of Cardiology·JournalEP Europace·DateMar 29, 2025

Innovative phospholipids enhance mRNA delivery

A new class of zwitterionic phospholipids, DOPE-Cx, enhances the functional delivery of mRNA via lipid nanoparticles, overcoming endosomal escape and improving mRNA expression. This breakthrough paves the way for advanced therapeutic applications, including mRNA vaccines, cancer treatment, and protein replacement therapy.

SourceHokkaido University·JournalAdvanced Science·TypeExperimental study·DateMar 28, 2025

Digital PCR can reliably determine if chronic myeloid leukemia patients in remission can successfully discontinue drug treatment

Researchers found that digital PCR for BCR::ABL1 is more sensitive and accurate than conventional real-time quantitative PCR to detect ultralow levels of residual leukemic disease. The technology enabled the detection of stable deep molecular remission in 97% of patients, allowing for safe discontinuation of treatment.

SourceElsevier·JournalJournal of Molecular Diagnostics·TypeExperimental study·DateMar 27, 2025

Revolutionizing protein modification: a new frontier in cancer research

A team of scientists has created a new method to selectively modify specific proteins in complex biological environments. They achieved this using aptamers and deoxyoxanosine, allowing precise conjugation of desired sites on target proteins. This breakthrough technology has the potential to revolutionize cancer diagnosis and treatment.

SourcePohang University of Science & Technology (POSTECH)·JournalJournal of the American Chemical Society·DateMar 26, 2025

UT Health San Antonio-led research discovers a way to slow or block recurrence of glioblastoma

Researchers at UT Health San Antonio have discovered a way to delay or even block recurrence of the deadliest brain cancer after radiation by targeting senescent cells with experimental 'senolytic' drugs. This approach shows promise in preventing tumor growth and improving patient survival.

SourceUniversity of Texas Health Science Center at San Antonio·JournalEMBO Molecular Medicine·TypeExperimental study·DateMar 26, 2025

Results of the INHALE-3 extension study: inhaled technosphere insulin plus insulin degludec in T1D

The INHALE-3 extension study found that a regimen of inhaled technosphere insulin and insulin degludec reduced post-meal hyperglycemia in adults with type 1 diabetes. The treatment showed significant improvements in mean time in range, with 43% of participants expressing interest in continuing the regimen.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalDiabetes Technology & Therapeutics·TypeRandomized controlled/clinical trial·DateMar 22, 2025

Evaluating DNA impurities in recombinant adeno-associated virus

A new study found that recombinant adeno-associated virus (rAAV) capsids contain single-stranded DNA impurities derived from plasmid and host cell DNA. The researchers suggest that the adverse effects of these impurities may differ from those of double-stranded DNA, highlighting the need for further evaluation.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalHuman Gene Therapy·TypeExperimental study·DateMar 22, 2025

WIN Consortium leading the future of precision cancer medicine

The WIN Consortium is transforming cancer care through personalized medicine, leveraging AI, molecular profiling, and clinical trials. The organization's innovations, including N-of-1 clinical trials and WINTHER and WINGPO trials, are helping clinicians make more precise treatment decisions and improving outcomes for cancer patients.

SourceImpact Journals LLC·JournalOncotarget·TypeNews article·DateMar 18, 2025

Efficient development of drugs with fewer mice

Researchers at the University of Zurich have developed a technology to test 25 antibodies simultaneously in a single mouse, greatly reducing the number of laboratory animals required. The method uses protein fragments as barcodes for analysis, allowing for high-quality preclinical data on multiple antibody candidates.

SourceUniversity of Zurich·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateMar 18, 2025

Chemo-immunotherapy approach shows potential benefit in patients with advanced HPV-negative head and neck cancer

A Phase 2 clinical trial found that a neoadjuvant chemo-immunotherapy regimen achieved a 53% deep response rate, exceeding historical data with chemotherapy alone. The treatment approach led to impressive survival outcomes and fewer toxic side effects in patients with advanced HPV-negative head and neck cancer.

SourceUniversity of Chicago Medical Center·JournalJAMA Oncology·TypeRandomized controlled/clinical trial·DateMar 6, 2025

Innovations in core-shell nanoparticles advancing drug delivery and precision medicine

Core-shell nanoparticles offer effective drug encapsulation, shielding from degradation, and controlled release. This innovation enables targeted drug delivery, improving treatment outcomes and reducing side effects. The versatility of these nanoparticles allows for tailored materials to suit different therapeutic needs.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalOMICS A Journal of Integrative Biology·TypeLiterature review·DateMar 5, 2025

Pusan National University researchers developed an advanced AI model for accelerating therapeutic gene target discovery

The new AI model leverages hypergraphs to quickly and accurately identify therapeutic gene targets for diseases. HIT outperformed existing models in all tested metrics, demonstrating its accuracy in classifying therapeutic gene targets with great precision.

SourcePusan National University·JournalBriefings in Bioinformatics·TypeComputational simulation/modeling·DateMar 5, 2025